No Cover Image

Journal article 52 views 2 downloads

Further Validation of the Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy

Laith Alrubaiy Orcid Logo, Rafid Sikafi Orcid Logo, Hayley Hutchings Orcid Logo, Ian Arnott, John Williams

Clinics and Practice, Volume: 12, Issue: 3, Pages: 436 - 448

Swansea University Authors: Laith Alrubaiy Orcid Logo, Hayley Hutchings Orcid Logo, John Williams

  • clinpract-12-00048.pdf

    PDF | Version of Record

    Copyright: © 2022 by the authors. This is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license

    Download (268.97KB)

Abstract

Background: Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) is a validated questionnaire to measure the quality of life (QoL) in Inflammatory Bowel Disease (IBD). However, it does not have stoma-specific questions and can be lengthy. This study aimed to validate a subset of the CUCQ-32 tha...

Full description

Published in: Clinics and Practice
ISSN: 2039-7283
Published: MDPI AG 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa60169
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: Background: Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) is a validated questionnaire to measure the quality of life (QoL) in Inflammatory Bowel Disease (IBD). However, it does not have stoma-specific questions and can be lengthy. This study aimed to validate a subset of the CUCQ-32 that would be suitable for patients with a stoma. Methods: Baseline data were collected from a cohort of patients with acute ulcerative colitis who were participating in the CONSTRUCT multicentre clinical trial. A subset of the CUCQ-32 questions was selected by stepwise regression. Further validation was examined using data from the UK IBD biological therapies audit. Construct validity was carried out using the EuroQol 5 dimensions (EQ5D) questionnaire, Simple Clinical Colitis Activity Index (SCCAI), and the Harvey–Bradshaw Index (HBI). Results: Using the data from 124 patients, a short-version questionnaire (CUCQ-12) was developed. Data from 484 patients with IBD (382 patients with Crohn’s disease, 76 patients with ulcerative colitis, and 26 patients with IBD-Unclassified) and 61 patients with stoma provided further validation of the CUCQ-12. A literature review and an expert focus group identified supplementary stoma-specific questions for the CUCQ-12+. The CUCQ-12+ demonstrated excellent internal consistency (Cronbach’s α = 0.86); established effective reproducibility (intra-class correlation coefficient = 0.74); correlated well with the EQ5D (r= −0.48), HBI (r = 0.45), and SCCAI (r = 0.43); and represented good responsiveness statistics (>0.5). Conclusions: CUCQ-12+ is a valid and reliable QoL measure used for all patients with IBD in clinical practice, including patients with a stoma.
Item Description: The data presented in this study are available on request from the corresponding author.
Keywords: quality of life; Inflammatory Bowel Disease; Crohn’s disease; ulcerative colitis; Patients Reported Outcomes
College: Swansea University Medical School
Funders: This research received no external funding.
Issue: 3
Start Page: 436
End Page: 448